DCM
TRIL

DAFNA Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

DAFNA Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$88K – 85
2017
Q2 		$88K Buy
+20,000
New +$111K 0.06% 74

Other funds holding TRIL

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DAFNA Capital Management's TRIL Position: Q3 2017 in Review

DAFNA Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2017, closing a stake of 20,000 shares — an estimated $88K sold.

DAFNA Capital Management first reported a position in TRIL in Q2 2017 and held it in 1 quarter. The position peaked at $88K in Q2 2017. 20 funds tracked by Wall St. Rank hold TRIL as of Q3 2017.

  • DAFNA Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 20,000 Trillium Therapeutics Inc. shares in Q3 2017, an estimated $88K.
  • DAFNA Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2017 and held it in 1 quarter.
  • DAFNA Capital Management's Trillium Therapeutics Inc. position peaked at $88K in Q2 2017.
  • 20 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.